Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer
EntreMed Presents Multi-Mechanism Results for ENMD-1198 at AACR Annual Meeting
May 1st, 2007
EntreMed, Inc. (NASDAQ:ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, announced the presentation of preclinical data for its clinical-stage product candidate, ENMD-1198. The data were presented by EntreMed scientists and collaborators during two separate sessions at the American Association for Cancer Research (AACR) Annual Meeting being held this week in Los Angeles, California. ENMD-1198, a new chemical entity (NCE) based on a modified chemical structure of 2-methoxyestradiol (2ME2), is designed to decrease metabolism while retaining 2ME2's multiple mechanisms of action, including inducing...
Source: Cancer Weekly (2007-05-01)
|
